The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Chengdi WangWenliang QiaoYuting JiangMin ZhuJun ShaoTao WangDan LiuWei-Min LiPublished in: Journal of cellular physiology (2019)
Pembrolizumab plus platinum-based chemotherapy was recommended as the optimal first-line therapy for advanced patients with NSCLC. Additionally, PD-L1 alone is not recommended as an adequate molecular biomarker to identify eligible patients for routine clinical practice in immunotherapy.
Keyphrases
- small cell lung cancer
- advanced non small cell lung cancer
- clinical practice
- end stage renal disease
- epidermal growth factor receptor
- ejection fraction
- newly diagnosed
- chronic kidney disease
- locally advanced
- prognostic factors
- peritoneal dialysis
- single cell
- patient reported outcomes
- radiation therapy
- patient reported